TIGIT Enhances Antigen-Specific Th2 Recall Responses and Allergic Disease

Evangelina Kourepini, Nikolaos Paschalidis, Davina Camargo Madeira Simoes, Maria Aggelakopoulou, Jane Grogan, Vily Panoutsakopoulou

Research output: Contribution to journalArticlepeer-review

36 Citations (Scopus)


T cell Ig and ITIM domain receptor (TIGIT), expressed on T, NK, and regulatory T cells, is known as an inhibitory molecule that limits autoimmunity, antiviral and antitumor immunity. In this report, we demonstrate that TIGIT enhances Th2 immunity. TIGIT expression was upregulated in activated Th2 cells from mice with experimental allergic disease and in Th2 polarization cultures. In addition, its high-affinity ligand CD155 was upregulated in mediastinal lymph node dendritic cells from allergic mice. In an in vitro setting, we observed that Tigit expression in Th2 cells and its interaction with CD155 expressed in dendritic cells were important during the development of Th2 responses. In addition, blockade of TIGIT inhibited Th2, but had no effect on either Th1 or Th17 polarization. In vivo blockade of TIGIT suppressed hallmarks of allergic airway disease, such as lung eosinophilia, goblet cell hyperplasia, Ag-specific Th2 responses, and IgE production, and reduced numbers of T follicular helper and effector Th2 cells. Thus, TIGIT is critical for Th2 immunity and can be used as a therapeutic target, especially in light of recent findings showing TIGIT locus hypomethylation in T cells from pediatric patients with allergic asthma.
Original languageEnglish
Pages (from-to)3570-3580
JournalThe Journal of Immunology
Publication statusPublished - 1 May 2016
Externally publishedYes


Dive into the research topics of 'TIGIT Enhances Antigen-Specific Th2 Recall Responses and Allergic Disease'. Together they form a unique fingerprint.

Cite this